Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Persist AI Adopts Scispot to operate as a Digital Biotech company


News provided by

Scispot

Jun 28, 2023, 15:45 ET

Share this article

Share toX

Share this article

Share toX

Scispot —  The Best Tech Stack for Modern Biotech
Scispot — The Best Tech Stack for Modern Biotech

Persist AI leverages Scispot's advanced tech stack to automate research workflows and scale AI capabilities, accelerating drug formulation development.

KITCHENER, Ontario, June 28, 2023 /PRNewswire-PRWeb/ -- Scispot, the creator of the best tech stack for modern biotech, announces that Persist AI, an AI-driven biotech company specializing in the creation of long-acting microsphere formulations, has selected them to provide a robust data infrastructure. This partnership aims to automate Persist AI's research workflows and scale its AI capabilities. Persist AI is currently utilizing Scispot as its primary data and workflow management platform, effectively gathering and integrating data from diverse sources, thereby optimizing its use in machine learning and artificial intelligence processes.

Persist AI is committed to slashing drug formulation development time by 50% to just 2 years through the power of AI-driven automation. Traditional methods would typically see pharmaceutical companies investing approximately five years to develop long-lasting drug formulations. However, with Persist AI's integration of advanced AI automation, the process is accelerated, targeting a 50% reduction in overall development time. Using Scispot's flexible platform, Persist AI is geared towards designing long-lasting injections that allow for slow drug release over prolonged periods. The AI models, trained using patterns extrapolated from a range of experiments, predict drug release rates and enhance formulation efficiency. This game-changing approach is set to revolutionize patient experience and adherence to treatments.

“As an AI-focused biotech company, digitizing and automating our processes from the get-go has been imperative. Scispot has been instrumental in establishing the right digital foundation to achieve this objective."

Post this

"As an AI-focused biotech company, digitizing and automating our processes from the get-go has been imperative. Scispot has been instrumental in establishing the right digital foundation to achieve this objective," stated Karthik Raman, Founder & CEO of Persist AI. "Scispot organizes not just experimental, but also organizational data, optimizing resource utilization. With the aid of Scispot's robust data management system, we have been able to connect our in silico data with the automated experiments we perform in the real world and to track resources like lab materials which are utilized in each batch."

"We at Scispot feel a deep synergy with Persist AI's objective, which resonates with our mission of reducing the time it takes to bring new drugs to market," stated Guru Singh, Founder & CEO of Scispot. "We strive to empower modern biotech companies with our advanced data infrastructure, supporting their transformation into full-fledged Digital Biotech entities. Persist AI epitomizes this transformation, and we are thrilled to support their commitment to delivering life-saving solutions more rapidly to the marketplace."

Persist AI's digital transformation journey with Scispot has yielded substantial enhancements in their research and development processes. Formerly dependent on Excel and Google Sheets, Persist AI required a solution capable of efficiently accommodating their growing demands, all while preserving comprehensive versioning and data integrity. Scispot's extensive capabilities have established a centralized hub, negating the necessity to manage numerous Excel sheets and facilitating smooth permissions for team members. The implementation of Scispot has led to improved organization, streamlined procedures, and automated data management.

As the digital era evolves, Scispot has secured its position as the tech stack of choice for modern biotech companies, particularly those focusing on machine learning and artificial intelligence. With its API-friendly electronic lab notebook (ELN) and lab information management system (LIMS), Scispot expertly marshals all R&D data. This strategic approach paves the way for smooth integration with advanced machine learning and AI, enabling companies to expedite their path to groundbreaking innovations.

ABOUT SCISPOT
Scispot is a Y Combinator-backed life science informatics company based in the Kitchener-Waterloo and Seattle area. Scispot has created the best tech stack to help modern biotechs evolve into efficient, scalable TechBio companies. Scispot's toolkit makes biotech R&D templatizable and programmable, enabling companies to automate lab management, centralize data, establish repeatable workflows, and comply with regulatory guidelines. To learn more, please visit http://www.scispot.com.

ABOUT PERSIST AI
Persist AI is a pioneering biotech company using artificial intelligence and machine learning to drastically expedite the development of long-acting, extended-release drug formulations. With a commitment to reducing traditional development time by 50%, Persist AI enables pharmaceutical manufacturers to optimize drug loading, morphology, and distribution, delivering solutions in weeks instead of years. Persist AI's innovative approach is revolutionizing the treatment of chronic conditions such as cancer and diabetes by significantly accelerating the drug formulation process. To learn more, please visit http://www.persist-ai.com.

Media Contact

Guru Singh, Scispot, 4255004629, [email protected]

SOURCE Scispot

Modal title

Persist AI Adopts Scispot to operate as a Digital Biotech company
Persist AI Adopts Scispot to operate as a Digital Biotech company
Persist AI Adopts Scispot to operate as a Digital Biotech company

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.